|
Gender: male/female
|
1.21 (0.68–2.18)
|
0.517
| | |
|
Age at operation
|
1.01 (0.99–1.04)
|
0.400
| | |
|
Preoperative chemotherapy (no/yes)
|
0.79 (0.40–1.55)
|
0.489
| | |
|
Synchronous/metachronous
|
0.80 (0.44–1.47)
|
0.476
| | |
|
Site of original (colon/rectum)
|
2.13 (1.16–3.92)
|
0.015
|
1.71 (0.913–3.20)
|
0.094
|
|
Histology (adenocarcinoma/mucinous)
|
1.65 (0.92–3.00)
|
0.096
| | |
|
Preoperative CEA level
|
1.00 (0.99–1.01)
|
0.161
| | |
|
Preoperative CA19–9 level
|
1.00 (0.99–1.01)
|
0.342
| | |
|
Liver metastases (no/yes)
|
1.36 (0.67–2.74)
|
0.397
| | |
|
HIPEC regimen (lobaplatin/non-lobaplatin)
|
1.60 (0.87–2.95)
|
0.134
| | |
|
Presence of ascites (no/yes)
|
1.34 (0.74–2.40)
|
0.335
| | |
|
PCI score
|
1.01 (1.05–1.15)
|
< 0.001
|
1.07 (1.01–1.14)
|
0.015
|
|
CC score (0–1/2–3)
|
3.36 (1.85–6.08)
|
< 0.001
|
1.92 (0.96–3.83)
|
0.064
|
|
Grade 3–4 Postoperative complication (no/yes)
|
2.71 (1.48–4.94)
|
0.001
|
1.86 (1.22–3.51)
|
0.044
|
|
Leukopenia (no/yes)
|
1.31 (0.61–2.83)
|
0.487
| | |
|
Neutropenia (no/yes)
|
1.31 (0.47–3.70)
|
0.605
| | |
|
Thrombocytopenia (no/yes)
|
1.45 (0.80–2.66)
|
0.224
| | |
